A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02 [0.03%]
rucaparib联合nivolumab作为晚期胆道癌维持治疗的II期多中心临床试验:BilT-02研究
Arathi Mohan,Kent A Griffith,Laura W Goff et al.
Arathi Mohan et al.
Purpose: This phase 2 trial investigated rucaparib (PARP inhibitor) in combination with nivolumab in patients with advanced BTC without progression after 4-6 months of first-line platinum-based chemotherapy. ...
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial [0.03%]
抗原受体修饰的T细胞治疗复发/难治性CD30阳性淋巴瘤的长期随访结果:一项单臂、多中心的I-II期临床试验
Xiangmin Wang,Qing Zhang,Dongmei Yan et al.
Xiangmin Wang et al.
Purpose: This report presents long-term outcomes of third-generation anti-CD30 CAR T-cell therapy in relapsed/refractory (r/r) CD30+ lymphoma patients. Pa...
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT) [0.03%]
利用机器学习识别多模态标志物,为接受度伐利尤单抗联合曲美木单抗和化疗治疗可获益的患者(TRIDENT研究)
Ferdinandos Skoulidis,Salma K Jabbour,Edward B Garon et al.
Ferdinandos Skoulidis et al.
Purpose: POSEIDON (NCT03164616) was a randomized, open-label, multicenter phase 3 trial comparing first-line durvalumab with or without tremelimumab in combination with chemotherapy versus chemotherapy alone in patients w...
A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancer [0.03%]
用于治疗前列腺癌患者的分批给药及多次循环的靶向抗PSMA放射性发射体225Ac-J591 I期剂量递增/扩展研究
Scott T Tagawa,Charlene Thomas,Abdul Baseet Arham et al.
Scott T Tagawa et al.
Purpose: To test safety of two regimens at differing levels of radioactivity of PSMA-targeted alpha radionuclide 225Ac-J591. Patients and methods: ...
Network Integrated Platform for Clinical Trials Navigation from the New South Wales Early Phase Clinical Trials Alliance [0.03%]
新南威尔士早期临床试验联盟的临床试验导航集成平台
Jia Liu,Max Farrow,Sandra S Hsing et al.
Jia Liu et al.
Purpose: Access to early-phase clinical trials (EPCTs) is increasingly constrained by delays in genomic testing and lack of coordinated system-level navigation. The New South Wales Early Phase Clinical Trials Alliance (NE...
Kasidy Brown,Noah I Hornick,Megan K Ruhland
Kasidy Brown
The ability of an individual's immune system to mount a productive response against the tumor is critical for the success of immunotherapy. Clinical trials in multiple tumor types have revealed that the degree and way in which any one perso...
Targeting CD24 activates macrophages to reduce tumor burden in preclinical models of solid tumors [0.03%]
靶向CD24可在实体瘤的小鼠模型中激活巨噬细胞并减少肿瘤负荷
Douglas V Faget,Rachel E Brewer,Joseane Sampaio et al.
Douglas V Faget et al.
Purpose: CD24 is a "don't eat me" signal overexpressed across multiple solid tumors and contributes to immune evasion by suppressing macrophage-mediated phagocytosis. Targeting the CD24/Siglec-10 axis represents a novel i...
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool [0.03%]
来那度胺致多发性骨髓瘤患者腹泻与肠道微生态失调及胆汁酸紊乱相关
Kevin Charles Miller,Teng Fei,Ruben J Faustino Ramos et al.
Kevin Charles Miller et al.
Purpose: Lenalidomide is integral to multiple myeloma therapy, but long-term use is frequently complicated by diarrhea, which diminishes patient quality-of-life. The pathophysiology of lenalidomide-related diarrhea (LRD) ...
Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity [0.03%]
替西妥珠单抗治疗患者的分子分型确定了与临床活性相关的免疫途径
Sriram Sridhar,Guy Roukens,Christina Y Yu et al.
Sriram Sridhar et al.
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)-specific antibody-drug conjugate that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expressio...
Targetable S100-RAGE signaling mediates intrinsic trastuzumab deruxtecan resistance in metastatic breast cancer [0.03%]
靶向S100-RAGE信号通路可介导转移性乳腺癌对曲拉西利的内在耐药性
Wenjuan Dong,Shiruo Wang,Bill Chan et al.
Wenjuan Dong et al.
Purpose: Trastuzumab deruxtecan (T-DXd) has improved outcomes in metastatic breast cancer; however, a substantial subset of patients experience early lack of clinical benefit that is not reliably predicted by routine clin...